SCHEMBL2383530

SCHEMBL2383530

Nc1nccc(COc2ccccc2N2CCN(C(=O)Nc3cc(C(F)(F)F)ccc3F)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TRPV1 Q8NER1 6/20 0.44
PDGFRB P09619 1/20 0.43
MAPK1 P28482 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
NPC1 O15118 1/20 0.43
KDM4E B2RXH2 3/20 0.41
RBP4 P02753 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385822 0.90 TRPV1 (0.46) USP2LMNATP53POLBALOX15
SCHEMBL2385197 0.87 MAPT (0.49) MAPTUSP2TSHRHSD17B10TRPV1
SCHEMBL2386092 0.87 TRPV1 (0.47) MAPTHSD17B10TRPV1PDGFRBMAPK1
SCHEMBL2385067 0.86 MAPT (0.45) MAPTPOLBTRPV1PDGFRBMAPK1
SCHEMBL2385169 0.85 TRPV1 (0.43) MAPTTRPV1MAPK1NPSR1KDM4E
SCHEMBL2384209 0.84 TRPV1 (0.40) USP2LMNATP53POLBALOX15
SCHEMBL2733022 0.83 TRPV1 (0.45) USP2TSHRHSD17B10TRPV1PDGFRB
SCHEMBL2384340 0.82 MAPT (0.45) MAPTUSP2LMNATP53POLB
SCHEMBL2384180 0.81 RBP4 (0.47) MAPTUSP2LMNATP53POLB
SCHEMBL2385620 0.81 MAPT (0.51) MAPTPOLBPDGFRBMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR MAPT 2716/4885USP2 1023/4885LMNA 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.